TWC
PSTX

TD Waterhouse Canada’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

TD Waterhouse Canada’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,500
Closed -$3.75K – 1800
2022
Q2 		$3.75K Hold
1,500
– – ﹤0.01% 1442
2022
Q1 		$7.11K Hold
1,500
– – ﹤0.01% 1395
2021
Q4 		$10.3K Buy
+1,500
New +$10.2K ﹤0.01% 1337

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

TD Waterhouse Canada's PSTX Position: Q3 2022 in Review

TD Waterhouse Canada sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q3 2022, closing a stake of 1,500 shares — an estimated $3.75K sold.

TD Waterhouse Canada first reported a position in PSTX in Q4 2021 and held it in 3 quarters. The position peaked at $10.3K in Q4 2021. 68 funds tracked by Wall St. Rank hold PSTX as of Q3 2022.

  • TD Waterhouse Canada reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • TD Waterhouse Canada sold 1,500 Poseida Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $3.75K.
  • TD Waterhouse Canada first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • TD Waterhouse Canada's Poseida Therapeutics, Inc. Common Stock position peaked at $10.3K in Q4 2021.
  • 68 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q3 2022.

Based on TD Waterhouse Canada's 13F filing for Q3 2022, filed 13 Nov 2023.